Clearmind Medicine (NASDAQ:CMND) Announces Quarterly Earnings Results

Clearmind Medicine (NASDAQ:CMND) released its quarterly earnings results on Wednesday. The company reported ($0.11) EPS for the quarter, Zacks reports.

Clearmind Medicine Stock Down 1.3 %

CMND traded down $0.02 during trading hours on Friday, hitting $1.47. 7,171 shares of the company’s stock were exchanged, compared to its average volume of 233,085. The firm has a 50 day moving average of $1.40 and a 200 day moving average of $1.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.71 and a quick ratio of 1.71. Clearmind Medicine has a 12-month low of $0.95 and a 12-month high of $2.30.

About Clearmind Medicine

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.